跳至主要内容
临床试验/NCT05100368
NCT05100368已完成不适用

The Prognostic Value of Serum Biomarkers in Ewing's Sarcoma

Istituto Ortopedico Rizzoli1 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2021年4月2日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
1,000
试验地点
1
主要终点
5-year survival

研究概览

简要总结

Extraction of laboratory data from blood tests prior to surgical and chemotherapy and other histological, clinical and instrumental data related to the patient's history from the digitized medical Digitized medical records and analysis of the same. The medical records of 1000 patients from January 1, 2000, until December 31, 2020

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
2 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with Ewing's Sarcoma and osteosarcoma with established diagnosis;
  • Patients with age ≥ 2 years;
  • Minimum follow-up duration of 2 years;
  • Medical records, complete blood work and instrumental examinations; Regular follow-up.

排除标准

  • Patients with Ewing's sarcoma or osteosarcoma who have received medical treatment (surgery radiotherapy or chemotherapy) in other institutions prior to admission to the Rizzoli Orthopaedic Institute.

结局指标

主要结局

5-year survival

时间窗: at baseline (Day0)

Evaluation of 5-year survival in relation to histologic, laboratory, clinical, and instrumental laboratory, clinical and instrumental factors

次要结局

  • Rate of local recurrence(at baseline (Day0))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Costantino Errani

Principal Investigator

Istituto Ortopedico Rizzoli

研究点 (1)

Loading locations...

相似试验

The Prognostic Value of Serum Biomarkers in Ewing's... | 临床试验